Abstract: The present invention relates to a means of controlling infection persistence of Helicobacter pylori (H. pylori). In particular, the present invention relates to an isolated, genetically modified Helicobacter pylori comprising a functional urease, wherein the contiguous amino acid sequence between amino acid 529 and amino acid 555 of SEQ ID NO:1 is altered to produce said modified Helicobacter pylori which is unable to establish or maintain a persistent infection.

Abstract: The present invention relates to strains of Helicobacter pylori useful for the delivery of biologically active agents. In particular, the present invention provides an isolated strain of H. pylori having: (a) low pathogenicity; (b) ability to naturally transform; and (c) ability to colonise mouse stomach mucosa without host adaptation.

Abstract: The present invention relates to synthetic operons. In particular, the present invention relates to a synthetic operon for integration into a bacterial chromosome of a bacterium comprising a promoter operably-linked to at least two genes, wherein at least one gene is a gene of interest and at least one gene is a gene essential to said bacterium.

Abstract: Helicobacter based preparations comprising a pharmacologically active molecule of interest are disclosed, as well as methods of preparing and using said preparations. In particular, Helicobacter pylori vectors, vector plasmids and recombinant cells that include a sequence encoding a pharmacologically active molecule of interest useful in therapeutic treatments and/or vaccination against disease are provided. Delivery of the pharamacologically active molecules is provided at the mucosal surface, such as the gastric mucosa or nasal membranes, to provide effective and continuous delivery of a pharmacologically active agent. In some embodiments, the Helicobacter provides exposure of a desired molecule of interest though the surface of the Helicobacter, providing exposure of the antigen to the host at the gastric mucosa. Live Helicobacter pylori vaccines are also provided. Vectors and shuttle vector constructs of the Helicobacter are also disclosed.

Abstract: Helicobacter based preparations comprising a pharmacologically active molecule of interest are disclosed, as well as methods of preparing and using said preparations. In particular, Helicobacter pylori vectors, vector plasmids and recombinant cells that include a sequence encoding a pharmacologically active molecule of interest useful in therapeutic treatments and/or vaccination against disease are provided. Delivery of the pharamacologically active molecules is provided at the mucosal surface, such as the gastric mucosa or nasal membranes, to provide effective and continuous delivery of a pharmacologically active agent. Vectors and shuttle vector constructs are also provided.

Abstract: Helicobacter based preparations comprising a pharmacologically active molecule of interest are disclosed, as well as methods of preparing and using said preparations. In particular, Helicobacter pylori vectors, vector plasmids and recombinant cells that include a sequence encoding a pharmacologically active molecule of interest useful in therapeutic treatments and/or vaccination against disease are provided. Delivery of the pharamacologically active molecules is provided at the mucosal surface, such as the gastric mucosa or nasal membranes, to provide effective and continuous delivery of a pharmacologically active agent. Vectors and shuttle vector constructs are also provided.